How UpToDate plans to compete in the race for doctors' AI search tools For three decades, doctors went to UpToDate as a search tool. But as OpenEvidence, a startup building an AI-powered version, became one of the hottest in health tech this year, sweeping up both funding and ...

Signal or noise? > How UpToDate plans to compete in the race for doctors' AI
search tools >> Comment below! #strategy #competitiveintelligence #marketing #productmarketing #pharma #biotech #healthcare #pharmaceutical

What Were the Most Significant Inflection Points or Breakthroughs in Cell and Gene Therapy? - CGTLive® What Were the Most Significant Inflection Points or Breakthroughs in Cell and Gene Therapy?  CGTLive®

Signal or noise? > What Were the Most Significant Inflection Points or
Breakthroughs in Cell and Gene Therapy? - CGTLive® >> Comment below! #strategy #competitiveintelligence #marketing #biotech #healthcare #competitivemarketing #pharmaceutical #pharma

Eaton Helps Seattle City Light Strengthen Grid Planning to Meet Record-Setting Demand for Electricity PITTSBURGH–(BUSINESS WIRE)–Intelligent power management company Eaton is helping Seattle City Light modernize and future-proof its electrical grid to support growing energy demand driven by electrification and population growth. By implementing Eaton’s advanced grid planning software, the utility is streamlining project management with advanced modeling tools that help prioritize infrastructure investments and the integration of new …

Signal or noise? > Eaton Helps Seattle City Light Strengthen Grid Planning to
Meet Record-Setting Demand for Electricity >> Comment below! #mhealth #AI #industry40 #healthtech #IoT

Digital Health Coffee Time Briefing ☕ Today's edition of includes Lancashire and South Cumbria ICB's plans for the largest procurement of ambient voice technology in NHS history.

Signal or noise? > Digital Health Coffee Time Briefing ☕ >> Comment below! #mhealth #healthtech #AI #industry40 #IoT

Low vaccine uptake hampers Moderna earnings, including meager RSV sales Moderna posted $1 billion in third-quarter revenue, down 45% from the same period a year ago, as shrinking vaccine uptake and a continued inability to crack into the RSV market posed major challenges. As a ...

Signal or noise? > Low vaccine uptake hampers Moderna earnings, including
meager RSV sales >> Comment below! #strategy #competitiveintelligence #marketing #biotech #productmarketing #pharmaceutical #pharma #healthcare

Scam Ads Are Flooding Social Media. These Former Meta Staffers Have a Plan Rob Leathern and Rob Goldman, who both worked at Meta, are launching a new nonprofit that aims to bring transparency to an increasingly opaque, scam-filled social media ecosystem.

Signal or noise? > Scam Ads Are Flooding Social Media. These Former Meta
Staffers Have a Plan >> Comment below! #mhealth #industry40 #AI #IoT #healthtech

Skillz Announces Preliminary Third Quarter 2025 Results LAS VEGAS–(BUSINESS WIRE)–Skillz Inc. (NYSE: SKLZ) (“Skillz” or the “Company”), the leading mobile games platform provider bringing fair competition to players worldwide, today reported unaudited preliminary financial results for the third quarter ended September 30, 2025. Preliminary Third Quarter Financial Update (Unaudited): Revenue of $27.4 million. Gross profit of $24.0 million. Net loss of $17.4 …

Signal or noise? > Skillz Announces Preliminary Third Quarter 2025
Results >> Comment below! #IoT #healthtech #mhealth #industry40 #AI

Signal or noise? > AstraZeneca drops MASH drug over disappointing phase 2
data >> Comment below! #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #competitivemarketing #healthcare

My Arcade Atari Gamestation Go Review: Price, Specs, Availability High-class retro gaming dream, meet budget manufacturing reality.

Signal or noise? > My Arcade Atari Gamestation Go Review: Price, Specs,
Availability >> Comment below! #AI #mhealth #healthtech #IoT #industry40

Gene Therapy for Ultra-Rare Diseases Market Forecast 2035 | Key Driver, Restraint, and Growth Opportunity - openPR.com Gene Therapy for Ultra-Rare Diseases Market Forecast 2035 | Key Driver, Restraint, and Growth Opportunity  openPR.com

Signal or noise? > Gene Therapy for Ultra-Rare Diseases Market Forecast 2035 |
Key Driver, Restraint, and Growth Opportunity - openPR.com >> Comment below! #strategy #competitiveintelligence #marketing #healthcare #pharma #pharmaceutical #competitivemarketing #biotech

Wireless Mobility Automotive becomes a 100% German-owned company strengthening its role as a trusted Western supplier MUNICH–(BUSINESS WIRE)–Wireless Mobility, a leading provider of advanced cellular, automotive, smart and short-range modules, today announces that Wireless Mobility Automotive has become a wholly owned subsidiary of Wireless Mobility Holding GmbH, making the company a 100% German-owned enterprise. This milestone reinforces the company’s position as a transparent and independent Western supplier, fully aligned with the …

Signal or noise? > Wireless Mobility Automotive becomes a 100% German-owned
company strengthening its role as a trusted Western
supplier >> Comment below! #healthtech #mhealth #IoT #AI #industry40

Cell and Gene Therapy Today—November 6, 2025 This week’s cell and gene therapy update spotlights key developments, regulatory milestones, and the latest progress shaping the biopharma landscape. […] The post Cell and Gene Therapy Today—November 6, 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Cell and Gene Therapy Today—November 6, 2025 Comment below! #LucidQuest #PharmaCI

🚀 Big buzz at #ASGCT25: #GeneEditing & #CRISPR headlines, 20% data-driven talk, 85% positive vibes on breakthrough therapies for #DMD & #rarediseases!🧬 Download our full #socialmedia report! http://dlvr.it/TP6707 #GeneTherapy #SocialListening #LucidQuest
@ASGCTherapy @ESGCT

Signal or noise? > Apple close to deal to adopt Google AI model for Siri
overhaul - report >> Comment below! #IoT #AI #industry40 #mhealth #healthtech

Rare Disease Video Recap—November 6, 2025 🎯 Watch Our Video Summary Capturing Rare Disease News from the Last Two Weeks Dive deeper 🗓️ Explore weekly details […] The post Rare Disease Video Recap—November 6, 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Rare Disease Video Recap—November 6, 2025 Comment below! #LucidQuest #PharmaCI

From the United States to the European Union, this concise roundup spotlights pivotal regulatory milestones, policy shifts, and market access signals shaping the rare pipeline over the past two weeks. 🔬 Key highlights: 💼 Novartis–Avidity: Novartis to acquire Avidity for USD 12B, adding late-stage AOC RNA programs in DM1, FSHD and DMD. 🏛️ EU data policy op-ed: Chiesi executive urges EHDS and HTA alignment to harmonise rare-disease evidence and accelerate access. 📱 NORD IAMRARE app: New mobile companion aims to boost patient-reported data capture for rare-disease registries. 🧬 Koselugo EU approval: EC approves selumetinib for adult NF1 plexiform neurofibromas after Phase 3 KOMET. 🧪 MHRA reform paper: UK regulator floats single early approval with RWE monitoring to speed rare therapies. 🤝 ERDERA NSS grants: Up to €30k per event for cross-border rare disease and rare cancer networking. 🧫 Elfabrio re-exam: Chiesi/Protalix seek EMA re-examination to add every-4-weeks dosing in EU, E2W remains approved. 🧯 Kygevvi FDA nod: UCB wins first US approval for TK2 deficiency, oral solution for paediatric and adult patients. Chapters: 0:00 Introduction 0:08 Novartis–Avidity: Novartis to acquire Avidity for USD 12B, adding late-stage AOC RNA programs in DM1, FSHD and DMD 0:59 EU data policy op-ed: Chiesi executive urges EHDS and HTA alignment to harmonise rare-disease evidence and accelerate access 1:28 NORD IAMRARE app: New mobile companion aims to boost patient-reported data capture for rare-disease registries 2:01 Koselugo EU approval: EC approves selumetinib for adult NF1 plexiform neurofibromas after Phase 3 KOMET 2:28 MHRA reform paper: UK regulator floats single early approval with RWE monitoring to speed rare therapies 3:02 ERDERA NSS grants: Up to €30k per event for cross-border rare disease and rare cancer networking 3:24 Elfabrio re-exam: Chiesi/Protalix seek EMA re-examination to add every-4-weeks dosing in EU, E2W remains approved 3:52 Kygevvi FDA nod: UCB wins first US approval for TK2 deficiency, oral solution for paediatric and adult patients 4:23 How to reach us 📢 Stay Ahead in Rare Diseases Research! ✅ Like, share, and subscribe for future updates on Rare Diseases ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Rare Diseases innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #RareDiseases #OrphanDrugs #AOC #RNAtherapeutics #DM1 #FSHD #DMD #NF1 #Koselugo #EHDS #HTA #RWE #MHRA #NORD #PatientRegistries #FabryDisease #Elfabrio #TK2D #Kygevvi #Biopharma #HealthPolicy #ClinicalTrials #MarketAccess Rare Disease Update – November 6, 2025: Novartis–Avidity, Koselugo EU OK, FDA OKs Kygevvi and More

LucidQuest YouTube > Rare Disease Update – November 6, 2025: Novartis–Avidity, Koselugo EU OK, FDA OKs Kygevvi and More: From the United States to the European Union, this concise roundup spotlights pivotal regulatory milestones, policy shifts, and market… Subscribe for more! #LucidQuest #PharmaCI

Bed management system for mental health to go live in South West The South West Provider Collaborative will deploy an electronic referral and bed management solution for specialist mental health services.

Signal or noise? > Bed management system for mental health to go live in South
West >> Comment below! #industry40 #healthtech #mhealth #AI #IoT

Gene Therapy Media Market Is Booming Worldwide| Sarepta - openPR.com Gene Therapy Media Market Is Booming Worldwide| Sarepta  openPR.com

Signal or noise? > Gene Therapy Media Market Is Booming Worldwide| Sarepta -
openPR.com >> Comment below! #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #healthcare #pharmaceutical #pharma

What is Competitive Intelligence? A Guide by LucidQuest - LucidQuest Ventures The integration of AI in Medical Affairs teams revolutionizes healthcare from harnessing real-world evidence to transforming HCPs engagement.

Ever wonder how some companies always know what’s coming next? It’s not luck, it’s Competitive Intelligence.

Check out our guide 👉 http://dlvr.it/TP62nP to learn about the process, tools, benefits, and how every team can use CI to win.

Signal or noise? > Adyen Expands In Person Payments Offering With Launch of Two
New Terminals >> Comment below! #AI #healthtech #mhealth #IoT #industry40

Rare Disease Today—November 6, 2025 This week’s Rare Disease Update covers pivotal rare-disease developments and regulatory milestones, with added context on their significance. In Today’s […] The post Rare Disease Today—November 6, 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Rare Disease Today—November 6, 2025 Comment below! #LucidQuest #PharmaCI

Cardiovascular Video Recap—November, 6 2025 🎯 Watch Our Video Summary Capturing Cardiovascular News from the Last Two Weeks Dive deeper 🗓️ Explore weekly details and […] The post Cardiovascular Video Recap—November, 6 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Cardiovascular Video Recap—November, 6 2025 Comment below! #LucidQuest #PharmaCI

Lucid Diligence Brief: Braveheart Bio launches with $185M Series A Lucid Diligence Brief: Braveheart Bio launches with $185M Series A Professional audiences only. Not investment research or advice. UK readers: […] The post Lucid Diligence Brief: Braveheart Bio launches with $185M Series A appeared first on LucidQuest Ventures.

LucidQuest Views >>> Lucid Diligence Brief: Braveheart Bio launches with $185M Series A Comment below! #LucidQuest #PharmaCI

Cardiovascular Today—November, 6 2025 This week’s cardiology update spotlights key developments, regulatory milestones, and the latest progress shaping the biopharma landscape. In Today’s Newsletter […] The post Cardiovascular Today—November, 6 2025 appeared first on LucidQuest Ventures.

LucidQuest Views >>> Cardiovascular Today—November, 6 2025 Comment below! #LucidQuest #PharmaCI

Signal or noise? > Qualcomm beats quarterly outlook with sales up 10% >> Comment below! #mhealth #AI #IoT #healthtech #industry40

Checkmarx One Achieves ACN Level 2 Certification, Setting a New Standard for Software Security and Digital Sovereignty in Italy MILAN–(BUSINESS WIRE)–Checkmarx, the leader in cloud-native, agentic application security for enterprises, has officially achieved Level 2 certification from the Agenzia per la Cybersicurezza Nazionale (ACN), Italy’s National Cybersecurity Agency. This milestone confirms that Checkmarx’s application development and operational practices adhere to the agency’s highest standards for cybersecurity, governance, and risk management. As one of the …

Signal or noise? > Checkmarx One Achieves ACN Level 2 Certification, Setting a
New Standard for Software Security and Digital Sovereignty in
Italy >> Comment below! #AI #industry40 #mhealth #IoT #healthtech

Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates - Nasdaq Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates  Nasdaq

Signal or noise? > Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses
Revenue Estimates - Nasdaq >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #competitivemarketing #pharma

Ocugen Reports Progress in Gene Therapy Trials Amid Financial Losses - TipRanks Ocugen Reports Progress in Gene Therapy Trials Amid Financial Losses  TipRanks

Signal or noise? > Ocugen Reports Progress in Gene Therapy Trials Amid
Financial Losses - TipRanks >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #competitivemarketing #pharma

SERES Officially Listed on HKEX, Leveraging Dual “A+H” Capital Platforms to Power Global Expansion CHONGQING, China, Nov. 6, 2025 /PRNewswire/ — On November 5, SERES Group (stock code: 9927.HK) was officially listed on the Main Board of the Hong Kong Stock Exchange. With this milestone, SERES is now the first Chinese luxury new energy vehicle (NEV) maker to be listed on both the A-share and H-share markets. It is …

Signal or noise? > SERES Officially Listed on HKEX, Leveraging Dual “A+H”
Capital Platforms to Power Global Expansion >> Comment below! #mhealth #IoT #healthtech #industry40 #AI

Gene Therapy for Mental Illness: Just Around the Corner? - Psychiatry Online Gene Therapy for Mental Illness: Just Around the Corner?  Psychiatry Online

Signal or noise? > Gene Therapy for Mental Illness: Just Around the Corner? -
Psychiatry Online >> Comment below! #strategy #competitiveintelligence #marketing #pharmaceutical #biotech #healthcare #pharma #competitivemarketing